Thermo Fisher Scientific Mogamulizumab Humanized Recombinant Human Monoclonal Antibody

Applications

• ELISA (Assay-dependent)

Product Specifications

Product Specific Information

• Endotoxin level: < 0.01 EU/µg by LAL method
• Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
• Store at 2–8°C for one week.
• Store at -20 to -80°C for twelve months from the date of receipt.

Target Information

Mogamulizumab is a humanized monoclonal antibody directed against CC chemokine receptor 4 (CCR4). It is used for research related to Mycosis Fungoides (MF) and Sezary Syndrome (SS), which are subtypes of cutaneous T-cell lymphoma. These lymphomas occur when T cells become cancerous and typically affect the skin, causing various types of lesions.

On August 8, 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab injection (Poteligeo) for intravenous use in adult patients with relapsed or refractory MF or SS after at least one prior systemic therapy. The antibody is derived from Kyowa Hakko Kirin’s POTELLIGENT® technology, which enhances antibody-dependent cell-mediated cytotoxicity (ADCC). Approval in Japan was granted on April 30, 2012, for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.